Imipenem and Cilastatin and Relebactam
Brand names: Recarbrio · Active ingredient: Imipenem Anhydrous, Cilastatin, Relebactam Anhydrous
In short: RECARBRIO® is indicated in adult and pediatric patients weighing at least 2 kg for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible gram-negative microorganisms: Acinetobacter calcoaceticus-baumannii complex, En
What is Imipenem and Cilastatin and Relebactam used for?
RECARBRIO® is indicated in adult and pediatric patients weighing at least 2 kg for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible gram-negative microorganisms: Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella aerogenes,
Klebsiella oxytoca,
Klebsiella pneumoniae,
Pseudomonas aeruginosa, and Serratia marcescens.
RECARBRIO is indicated in adult and pediatric patients weighing at least 2 kg who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Approval of this indication is based on limited clinical safety and efficacy data for RECARBRIO . …
Imipenem and Cilastatin and Relebactam dosage
The recommended dosage of RECARBRIO is 1.25 grams (imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) administered by intravenous (IV) infusion over 30 minutes every 6 hours in adult patients with creatinine clearance (CLcr) of 90 mL/min or greater). The recommended duration of treatment with RECARBRIO is 4 days to 14 days. The duration of therapy should be guided by the severity and location of infection and clinical response.
The recommended dosage of RECARBRIO in pediatric patients weighing at least 2 kg varies by patient weight and age, with specific dosing recommendations shown in Table 1. The recommended duration of treatment with RECARBRIO is 4 days to 14 days. The duration of therapy should be guided by the severity and location of infection and clinical response.
RECARBRIO is not recommended in pediatric patients less than 37 weeks post-menstrual age (gestational age at birth plus post-natal age) .
RECARBRIO is not recommended for pediatric patients weighing less than 30 kg with renal impairment .
Age Range | Body Weight | Dose | Dosing Frequency | Infusion Duration
BirthPediatric patients from birth (includes pediatric patients at least 37 weeks post-menstrual age) to less than 3 months | 2 kg or greater | RECARBRIO 37.5Provides 15 mg/kg imipenem, 15 mg/kg cilastatin, and 7.5 mg/kg relebactam mg/kg | Every 8 hours | 60 minutes
3 months to less than 18 years | less than 30 kg | RECARBRIO 37.5 mg/kg | Every 6 hours | 60 minutes
3 months to less than 18 years | 30 kg or greater | RECARBRIO 1.25Provides 500 mg imipenem, 500 mg cilastatin, and 250 mg, relebactam grams | Every 6 hours | 30 minutes
Adult patients who have a CLcr less than 90 mL/min require dosage reduction of RECARBRIO. The recommended dosage of RECARBRIO in adult patients with renal impairment is shown in Table 2.
Creatinine Clearance (CLcr) ([mL/min)]CLcr calculated using the Cockcroft-Gault formula for adult patients. | DoseRECARBRIO is provided as a single vial in a fixed-dose combination; the dose for each component will be adjusted equally during preparation . | Dosing Frequency | Infusion Duration
60 to 89 | RECARBRIO 1 gramProvides 400 mg imipenem, 400 mg cilastatin, and 200 mg relebactam | Every 6 hours | 30 minutes
30 to 59 | RECARBRIO 0.75 gramsProvides 300 mg imipenem, 300 mg cilastatin, and 150 mg relebactam | Every 6 hours | 30 minutes
15 to 29 not receiving hemodialysis | RECARBRIO 0.5 gramsProvides 200 mg imipenem, 200 mg cilastatin, and 100 mg relebactam | Every 6 hours | 30 minutes
Receiving hemodialysisAdministration should be timed to follow hemodialysis and at intervals timed from the end of that hemodialysis session. …
How to take Imipenem and Cilastatin and Relebactam — instructions & advice from the label
Serious Allergic Reactions
Advise patients, their families, or caregivers that allergic reactions, including serious allergic reactions, could occur that require immediate treatment. Ask them about any previous hypersensitivity reactions to RECARBRIO (imipenem, cilastatin, and relebactam), carbapenems, penicillins, cephalosporins, other beta lactams, or other allergens .
Seizures and Central Nervous System Reactions
Counsel patients, their families, or caregivers to inform a healthcare provider if they have central nervous system disorders, such as stroke or history of seizures. Seizures have been reported during treatment with imipenem, a component of RECARBRIO, especially when recommended dosages were exceeded and with closely related antibacterial drugs .
Drug Interaction with Valproic Acid
Counsel patients, their families, or caregivers to inform a healthcare provider if they are taking valproic acid or divalproex sodium. If treatment with RECARBRIO is necessary, supplemental anti-convulsant medication to prevent and/or treat seizures may be needed . …
Warnings & precautions
Do not take this medicine if: RECARBRIO is contraindicated in patients with a history of known severe hypersensitivity (severe systemic allergic reaction such as anaphylaxis) to any component of RECARBRIO.
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta lactams. Before initiating therapy with RECARBRIO, careful inquiry should be made concerning previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, other beta lactams, and other allergens. If a hypersensitivity reaction to RECARBRIO occurs, discontinue the therapy immediately.
RECARBRIO is contraindicated in patients with a history of severe hypersensitivity to any component of RECARBRIO .
CNS adverse reactions, such as seizures, confusional states, and myoclonic activity, have been reported during treatment with imipenem/cilastatin, a component of RECARBRIO, especially when recommended dosages of imipenem were exceeded. These have been reported most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) and/or compromised renal function.
Anticonvulsant therapy should be continued in patients with known seizure disorders. If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether RECARBRIO should be discontinued.
Concomitant use of RECARBRIO, with valproic acid or divalproex sodium may increase the risk of breakthrough seizures. Avoid concomitant use of RECARBRIO with valproic acid or divalproex sodium or consider alternative antibacterial drugs other than carbapenems .
Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including RECARBRIO, and may range in severity from mild diarrhea to fatal colitis. …
Imipenem and Cilastatin and Relebactam side effects
The following serious adverse reactions are described in greater detail in the Warnings and Precautions section.
Hypersensitivity Reactions
Seizures and Other Central Nervous System Adverse Reactions
Increased Seizure Potential Due to Interaction with Valproic Acid
Clostridioides difficile-Associated Diarrhea (CDAD)
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adult Patients
Overview of the Safety Evaluation of RECARBRIO in Adult Patients
Safety was primarily evaluated in three active-controlled, double-blind trials in HABP/VABP, cUTI, and cIAI (Trials 1, 2, and 3, respectively).
In the HABP/VABP trial (Trial 1), patients were treated with either RECARBRIO or piperacillin and tazobactam (4.5 grams).
In the cUTI trial (Trial 2) and cIAI trial (Trial 3), patients in the treatment arms were treated with either imipenem 500 mg/cilastatin 500 mg and relebactam 250 mg or imipenem 500 mg/cilastatin 500 mg and relebactam 125 mg (not an approved dose), and patients in the control arm were treated with imipenem 500 mg/cilastatin 500 mg plus placebo (IV normal saline). Across Trials 2 and 3, the mean duration of IV therapy in patients treated with imipenem/cilastatin plus relebactam 250 mg was approximately 7 days. …
Drug interactions
Generalized seizures have been reported in patients who received ganciclovir concomitantly with imipenem/cilastatin, a component of RECARBRIO. Ganciclovir should not be used concomitantly with RECARBRIO unless the potential benefits outweigh the risks.
Based on case reports in the literature concomitant use of carbapenems, including imipenem/cilastatin, components of RECARBRIO, with valproic acid or divalproex sodium may decrease valproic acid concentrations which may increase the risk of breakthrough seizures . Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid's glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid. Avoid concomitant use of RECARBRIO with valproic acid or divalproex sodium. Consider alternative antibacterials other than carbapenems to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium.
About this medicine
RECARBRIO (imipenem, cilastatin, and relebactam) for injection is an antibacterial combination product consisting of imipenem, a carbapenem antibacterial drug, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a diazabicyclooctane beta-lactamase inhibitor, for intravenous administration.
Imipenem
Imipenem is a beta lactam antibacterial drug. Imipenem (N-formimidoylthienamycin monohydrate) is a crystalline derivative of thienamycin, which is produced by Streptomyces cattleya. The chemical name is (5R,6S)-3-[[2-(formimidoylamino)ethyl]thio]-6-[(R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate. It is an off-white, non-hygroscopic crystalline compound, sparingly soluble in water. The empirical formula is C12H17N3O4S∙H2O and the molecular weight is 317.37.
Figure 1: Chemical structure of imipenem
Cilastatin
Cilastatin sodium is the sodium salt of a derivatized heptenoic acid. The chemical name is sodium (Z)-7-[[(R)-2-amino-2-carboxyethyl]thio]-2-[(S)-2,2-dimethylcyclopropanecarboxamido]-2-heptenoate. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID be32f468-738b-40df-a425-591e12f65159. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin